Average cost of drugs for extensively drug-resistant tuberculosis in Argentina
Argentina: Average cost of drugs for extensively drug-resistant tuberculosis was 4,721 constant 2022 US$ in 2024. ◆ Volatile
Average cost of drugs for extensively drug-resistant tuberculosis in Argentina, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
In 2024, average cost of drugs for extensively drug-resistant tuberculosis in Argentina stood at 4,721 constant 2022 US$.
The figure is up 123.8% on the previous year and down 76.4% over ten years.
That places Argentina 12th out of 56 countries with data for 2024, putting it in the top quarter.
Average cost of drugs for extensively drug-resistant tuberculosis in Argentina, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 20,000 constant 2022 US$ | — |
| 2018 | 5,006 constant 2022 US$ | -75.0% |
| 2019 | 2,420 constant 2022 US$ | -51.7% |
| 2020 | 2,287 constant 2022 US$ | -5.5% |
| 2021 | 1,324 constant 2022 US$ | -42.1% |
| 2022 | 2,100 constant 2022 US$ | +58.6% |
| 2023 | 2,109 constant 2022 US$ | +0.4% |
| 2024 | 4,721 constant 2022 US$ | +123.9% |
Argentina compared with similar countries
- Argentina's 4,721 constant 2022 US$ is above the median for upper middle income countries, which is 2,000 constant 2022 US$, 2.4× the median. (23 countries reporting)
- Argentina's 4,721 constant 2022 US$ is above the median for Latin America & Caribbean, which is 3,884 constant 2022 US$, 1.2× the median. (9 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 9,142 constant 2022 US$ | 2,420 constant 2022 US$ | 20,000 constant 2022 US$ | 3 |
| 2020s | 2,508 constant 2022 US$ | 1,324 constant 2022 US$ | 4,721 constant 2022 US$ | 5 |
Countries ranked near Argentina
More reference data data for Argentina
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 1.56 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 20.99 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 37.41 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 5.76 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 37.41 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 5.24 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 1.69 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 111.77 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 187.7 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 31.35 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in Argentina?
- Average cost of drugs for extensively drug-resistant tuberculosis in Argentina was 4,721 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in Argentina?
- The highest recorded value was 20,000 constant 2022 US$ in 2017.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in Argentina?
- The lowest recorded value was 1,324 constant 2022 US$ in 2021.
- How does Argentina rank for average cost of drugs for extensively drug-resistant tuberculosis?
- Argentina ranks 12th out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in Argentina?
- Over the last ten years it is down 76.4%. The long-run trend across the full record is volatile.
- Where does this Argentina data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.